A study recently published in the journal The Lancet Child and Adolescent Health provides strong support for vaccinating pregnant women against RSV in order to prevent their infants from being hospitalized with RSV infections in the first 5 months of life. The U.S. Department of Health and Human Services (which oversees the CDC) has sent mixed messages about maternal RSV vaccination this year and as a result, many pregnant American women (and their doctors) are confused about whether or not to get vaccinated.
Respiratory syncytial virus (RSV) is a common respiratory virus that generally occurs in the winter. Nearly all children in the U.S. are infected by age 2-years-old and re-infections are very common. In children older than 4-years-old and adults younger than 65-years-old, RSV infections are relatively mild and frequently similar to a common cold. But in newborn infants and the elderly, RSV infections can be deadly. In young children, RSV causes bronchiolitis, a narrowing of the airways that can make it difficult to breathe. The treatment for most infants with bronchiolitis caused by RSV is primarily supportive, so testing for RSV as the specific viral cause of infant bronchiolitis is frequently not done since it will not affect treatment. Therefore, it is difficult to know exactly how many infants are hospitalized because of RSV. Instead, many epidemiologists use the hospital diagnosis of bronchiolitis as a surrogate for a diagnosis of RSV infection when studying infant hospital admissions (and deaths).
The CDC reported that between October 1, 2024 and May 3, 2025, an estimated 10,00 – 23,000 Americans died from RSV and an estimated 190,000 – 350,000 Americans were hospitalized with RSV (all ages combined). Compared to all other age groups, infants have the highest hospitalization rate with one out of every 100 infants in the U.S. hospitalized with RSV during the winter of 2024 – 2025 (light blue line in the graph below from the CDC’s RSV Net Interactive Dashboard). And last winter was a mild RSV season compared to previous years. For example, during the winter of 2022 – 2023, one out of every 49 infants in the U.S. was hospitalized with RSV (dark blue line in the graph below).

These are astoundingly high rates of infant hospitalizations. In contrast, only one out of every 5,300 American children between ages 5 – 18 years-old were hospitalized with RSV last winter. And only one out of every 10,000 adults between ages 18 – 50 years-old were hospitalized with RSV last winter.
The travesty is that most infant hospitalizations are avoidable by vaccinating the mothers during pregnancy. Two years ago, an RSV vaccine was approved by the FDA to be used in pregnant women. Its use is the likely reason that the 2024 – 2025 infant RSV season was so mild compared to previous years (as shown in the graph above). Currently, only the RSV vaccine made by Pfizer under the brand name Abrysvo is approved for use during pregnancy. Two other RSV vaccines are approved only for use in the elderly (Moderna’s mRESVIA and Pfizer’s Arexvy).
The recent study in The Lancet Child and Adolescent Health looked at 391 infants hospitalized with RSV in England and Scotland. All infants were between 0 – 5 months old. These infants were compared to control infants who were not hospitalized with RSV. The authors found that effectiveness of RSV vaccination at any time during pregnancy was 58% but if the RSV vaccination was given more than 2 weeks before delivery, the vaccination was 72% effective in preventing subsequent hospitalization of the infants due to an RSV infection. These results are similar to the study published in the New England Journal of Medicine in 2023 that led to the FDA approval of the Pfizer RSV vaccine for pregnant women.
What if a pregnant woman has already received an RSV vaccine in the past?
Currently, the CDC recommends that women only get vaccinated against RSV once. If a vaccinated woman then has a second pregnancy, then she is not supposed to be re-vaccinated. Instead, it is recommended that her infant receives a monoclonal antibody against RSV (nirsevimab) shortly after birth. This is different than recommendations for vaccinations against other respiratory viruses like COVID and influenza that are recommended to be repeated on a regular basis. However, it has been shown that immunity after an RSV vaccination wanes with time, so there is currently a phase III clinical trial looking at the safety and efficacy of re-vaccinating pregnant women against RSV during subsequent pregnancies. The results of this study will likely not be available for several years.
The CDC has sent confusing messages about RSV vaccination
Robert F. Kennedy, Jr. was appointed as Secretary of the Department of Health and Human Services on February 13, 2025. The immediate result was a retraction of many of the CDC websites containing information about vaccines. Notably, the CDC website “RSV Vaccine Guidance for Pregnant Women” was taken down only to have a court order the website to be restored on February 14, 2025. The top of the website now carries this disclaimer:

It is unclear why this disclaimer exists as there is no reference to gender ideology other than the mention of “pregnant women” on this webpage. But anyone reading the last sentence: “This page does not reflect biological reality and therefore the Administration and this Department rejects it.” would justifiably believe that the Trump administration rejects vaccinating pregnant women against RSV. Since his appointment, RFK, Jr. has fired all of the members of the CDC’s Advisory Committee on Immunization Practices (ACIP) and replaced them with notable vaccine skeptics. Thus far, the ACIP has not changed the recommendations for vaccinating pregnant women against RSV but has dropped the recommendation for vaccinating pregnant women against another respiratory virus, COVID.
The CDC’s current vaccination recommendations for pregnant women are complicated and confusing to many pregnant women. Currently, the CDC recommends vaccination for women who are between 32 weeks pregnant and 36 weeks 6 days pregnant. However, vaccinations should only be given September through January in most of the continental U.S. But if the pregnant women lives in Alaska, southern Florida, Guam, Hawaii, Puerto Rico, U.S.-affiliated Pacific Islands, or the U.S. Virgin Islands, then pregnant women should be vaccinated against RSV year-round. If the mother did not get an RSV vaccination during that particular pregnancy, then the infant should receive an RSV antibody (nirsevimab) injection but only during the months of October – March. For the average pregnant woman reading these recommendations, they are mind-bogglingly bewildering.
All of these factors together have led to public confusion about vaccinating pregnant women against RSV and have led to mistrust in vaccines in general.
So, what is a doctor to do?
More than ever before, it is incumbent on OB/GYN physicians, nurse midwives, family physicians, pediatricians, NPs, and PAs to provide guidance to their pregnant patients and and to mothers of newborn infants. Fortunately, death from RSV in infants is relatively uncommon because of advances in hospital treatment of infants with bronchiolitis. However, hospitalization because of RSV is all too common in American infants. Hospitalization is frightening for both the child and the parents. It necessitates emergently arranging childcare for other children and arranging someone to take care of the family dog. It means unexpected time off work for the parents. Every year, infant hospitalizations due to RSV cost the U.S. $710 million – that works out to $187 per every pregnancy. Even though most infants do not die from their RSV infection, it still extract a great emotional and financial cost.
The disclaimer on the CDC’s website about RSV vaccination and pregnancy is very disturbing because it implies that the Trump administration does not support vaccinating pregnant women against RSV. Moreover, the rise of anti-vaxxers into positions of government authority has resulted in greater skepticism about vaccines by the general public and has resulted in declining vaccination rates across the country. Educating our patients about the importance of RSV vaccination during pregnancy will take valuable time during office visits. But this will be time well spent by physicians, advance practice providers, and pharmacists.
July 23, 2025